Keyphrases
Post-traumatic Headache
67%
Headache
50%
Cluster Headache
48%
Migraine
43%
Placebo
43%
Calcitonin Gene-related Peptide
37%
Erenumab
32%
Migraine-like
31%
Vasoactive Intestinal Peptide
29%
Cromakalim
27%
Headache Attacks
25%
Vasoactive Intestinal Polypeptide
24%
Plasma Parameters
24%
Chronic Migraine
23%
Mild Traumatic Brain Injury (mTBI)
23%
Randomized Clinical Trial
22%
Single Center
20%
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)
20%
Healthy Volunteers
19%
Pituitary Adenylate Cyclase-activating polypeptide-38
19%
ATP-sensitive Potassium Channel
19%
Fremanezumab
19%
Tolerability
19%
Headache Intensity
18%
Migraine Attack
18%
Episodic Cluster Headache
13%
Intensity Score
13%
Chronic Cluster Headache
12%
Migraine without Aura (MWoA)
12%
Placebo-controlled
11%
Dizziness
11%
Migraine Prevention
11%
Non-associated
11%
Area under the Curve
10%
Randomized Placebo-controlled Trial
10%
Monthly Migraine Days
10%
Meta-analysis
9%
BK Channel
9%
Real-world Observational Study
9%
Osteoarthritis
9%
Healthy Individuals
9%
Calcitonin Receptor
9%
Prodromal Phase
9%
Extracranial
9%
Preventive Treatment
9%
CAMP Signaling
9%
Adenosine Triphosphate-sensitive Potassium Channels
9%
Vasodilation
9%
Mast Cell Activation
9%
Channel Opening
9%
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Headache
67%
Posttraumatic Headache
58%
Placebo
51%
Vasoactive Intestinal Polypeptide
48%
Calcitonin Gene Related Peptide
47%
Cluster Headache
38%
Transformed Migraine
32%
Erenumab
31%
Traumatic Brain Injury
31%
Adenosine Triphosphate Sensitive Potassium Channel
29%
Lemakalim
26%
Erethism
19%
Observational Study
19%
Fremanezumab
19%
Normal Human
19%
Adenylate Cyclase
19%
Tolerability
19%
Episodic Cluster Headache
13%
Chronic Cluster Headache
12%
Randomized Clinical Trial
12%
Dizziness
11%
Remission
10%
Hypophysis Adenylate Cyclase Activating Polypeptide
10%
Osteoarthritis
9%
Calcitonin Gene Related Peptide Receptor
9%
Adverse Event
9%
Phosphodiesterase III
9%
Vertigo
9%
Menstrual Migraine
9%
Large Conductance Calcium Activated Potassium Channel
9%
Symptom
9%
Monoclonal Antibody
8%
Flindokalner
8%
Receptor
6%
Channel Opener
5%
Cilostazol
5%
Histamine
5%
Tryptase
5%
Sodium Chloride
5%
Neuroscience
Migraine
97%
Headache
88%
Vasoactive Intestinal Peptide
38%
Placebo
37%
Adenosine Triphosphate Sensitive Potassium Channel
29%
Cluster Headache
29%
Calcitonin
21%
Neurotrauma
21%
Traumatic Brain Injury
21%
Adenylyl Cyclase
19%
Hypophysis Adenylate Cyclase Activating Polypeptide
10%
Cyclic Adenosine Monophosphate
9%
Calcitonin Gene-Related Peptide Receptor
9%
BK Channel
9%
Vasodilation
9%
Meta-Analysis
9%
Phosphodiesterase III
9%
Diffusion Tensor Imaging
9%
Monoclonal Antibody
5%